ERBB2 and neoplasm: The final diagnosis is based on immunohistochemical and cytogenetic tests to accurately assess tumor type, grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status (Mueller et al., 2018; Budny et al., 2019).